// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Biologic dmards and psoriatic arthritis in europe in 2016/2017: characteristics of patients starting tnf-inhibitors or ustekinumab in the ongoing psabio observational cohort study

L. Gossec - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Ustekinumab

Biomap® phenotypic profiling of two batches of originator etanercept reveals equivalent activity signatures consistent with conserved biological activity

A. O’Mahony - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Etanercept

Biomechanical therapy for osteoarthritis of the knee: a randomised controlled trial (BIOTOK

S. Reichenbach - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Biosimilar use in patients with juvenile idiopathic arthritis in a real-world setting in the united kingdom

D. De Cock - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Etanercept biosimilar

Bone marrow lesion type and pain in knee osteoarthritis

T.A. Perry - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Knee osteoarthritis

N/A

Bone mineral density at different sites as a predictor of rib fractures: a case-control study

H.L. Wu - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Cadmium toxicity as a probable cause of smoking induced bone loss

A.A. Elbeialy - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

cadmium

Can community pharmacy services be the missing link in achieving early diagnosis of psoriatic arthritis?

P. Mehra - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

N/A

Cardiovascular disease risk in clinical subtypes of psoriatic arthritis

N. Hassan - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

Cardiovascular risk age and vascular age estimations in predicting cardiovascular events in rheumatoid arthritis patients

G. Wibetoe - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Central sensitisationpredicts fatigue independently of musculoskeletal pain

K.L. Druce - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

N/A

Change in functional disability in acpa-positive arthralgia patients prior to progression to inflammatory arthritis

P. Pentony - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Change in muscle volume and muscle fat fraction as potential non-invasive biomarkers of disease progression: machine learning framework for quantitative analysis of mri data

D. Fischer - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Changes in incidence of shoulder, elbow, wrist and finger replacement surgery among rheumatoid arthritis patients following the introduction of biological dmards: an interrupted time series analysis using danish health care registers

R.L. Cordtz - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Changes in rheumatology provision and practice in a publicly-funded single payer healthcare system

J. Widdifield - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Characterisationof the molecular profile of altered genes and pathways in monocytes of antiphospholipid syndrome patients related to their atherothrombotic status. effects of in vivo ubiquinol supplementation

C. Perez-Sanchez - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Antiphospholipid syndrome

Coenzyme Q10

Clinical outcomes and response to anti-thrombotic treatment among patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicenter cohort study

S. Sciascia - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Thrombotic microangiopathy

N/A

Comparative effectiveness in pain and haq-di improvement for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in csdmard-naÏve rheumatoid arthritis patients: a matching-adjusted indirect comparison (MAIC

B. Fautrel - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Tocilizumab

Comparing adherence to treatment in lupus and vasculitis patients

E. Ntatsaki - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Comparing the clinical profile of adults and children with behÇet’s syndrome in the uk

S. Myers - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Behcet disease

N/A

Copyright © 2026. QuantiNova All rights reserved